Articles by Melissa Badamo
Tagraxofusp is the first drug for BPDCN, and the first CD123-targeting drug in oncology, to receive FDA approval.
Intravenous mosunetuzumab was administered in 21-day cycles, with step-up dosing integrated in cycle one.
Prefibrotic myelofibrosis is the focus of “SOHO State of the Art Updates and Next Questions.”
Early detection and prevention are particularly important in leukemia, Dr. Garcia-Manero explained.
Palliative care facilitates communication and helps with symptom management, the researchers noted.
Momelotinib achieved higher rates of transfusion independence compared with ruxolitinib.
Splenic irradiation before HSCT is associated with reduced spleen size and lower incidence of relapse in patients with MF.
Sotatercept monotherapy, and combined with ruxolitinib, is a safe and effective treatment for patients with PMF and anemia.
The ELM-2 trial studied odronextamab in patients with relapsed or refractory follicular lymphoma.
Donna Catamero, ANP-BC, OCN, CCRC, discusses selinexor for myeloma, the BOSTON trial, and other recent advances in myeloma.
A phase II study presented at ASPHO 2024 evaluated revumenib in KMT2A-rearranged ALL and AML.
Dr. Colla describes her current research at MD Anderson, such as developing new therapeutic approaches to MDS.
Dr. Bertoni and colleagues characterized two small nucleolar RNAs that exert tumor suppressor activity in DLBCL cells.
In approximately 12,000 reports of adverse events, the researchers found 19 cases of T-cell malignancies after CAR-T.
The average rate of progression for CHIP to MDS or AML is about 1% per year, Dr. Patel explained.
Dr. Vose discusses how she became a hematologist, how she nurtures her artistic side outside of work, and more.
The “real revolution” in myeloma is in the immune therapies, Dr. Anderson said, such as bispecific T-cell engagers and ...
Around 45% of patients had a complete response after cladribine, and 31% proceeded to transplant.
The researchers found that CALM-AF10 leukemia cells grow slower after the SIX1 knockdown.
The overall response rate was 71%, and the most common side effects were CRS, neutropenia, and anemia.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.